MX2016005166A - Derivados de tirosina y composiciones que los comprenden. - Google Patents

Derivados de tirosina y composiciones que los comprenden.

Info

Publication number
MX2016005166A
MX2016005166A MX2016005166A MX2016005166A MX2016005166A MX 2016005166 A MX2016005166 A MX 2016005166A MX 2016005166 A MX2016005166 A MX 2016005166A MX 2016005166 A MX2016005166 A MX 2016005166A MX 2016005166 A MX2016005166 A MX 2016005166A
Authority
MX
Mexico
Prior art keywords
solid particle
particle material
tyrosine derivative
compositions
tyrosine derivatives
Prior art date
Application number
MX2016005166A
Other languages
English (en)
Other versions
MX384083B (es
Inventor
Hoffman Steven
Original Assignee
Tyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tyme Inc filed Critical Tyme Inc
Publication of MX2016005166A publication Critical patent/MX2016005166A/es
Publication of MX384083B publication Critical patent/MX384083B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/02—Radiation therapy using microwaves
    • A61N5/022—Apparatus adapted for a specific treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0659—Radiation therapy using light characterised by the wavelength of light used infrared
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0661—Radiation therapy using light characterised by the wavelength of light used ultraviolet
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0662—Visible light
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se proporcionan en la presente métodos que comprenden proporcionar un derivado de tirosina y un material de partículas sólidas (y, opcionalmente melanina) y aplicar fuerza a dicho derivado de tirosina y dicho material de partículas sólidas durante un tiempo y bajo condiciones efectivas para impregnar al menos uno de dicho derivado de tirosina y dicho material de partículas sólidas con el otro de dicho derivado de tirosina y dicho material de partículas sólidas. La invención proporciona también composiciones que comprenden al menos uno de un derivado de tirosina impregnado con un material de partículas sólidas y material de partículas sólidas impregnado con un derivado de tirosina.
MX2016005166A 2013-10-22 2014-10-21 Derivados de tirosina y composiciones que los comprenden. MX384083B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361894279P 2013-10-22 2013-10-22
US14/062,194 US9585841B2 (en) 2013-10-22 2013-10-24 Tyrosine derivatives and compositions comprising them
PCT/US2014/061527 WO2015061288A1 (en) 2013-10-22 2014-10-21 Tyrosine derivatives and compositions comprising them

Publications (2)

Publication Number Publication Date
MX2016005166A true MX2016005166A (es) 2016-12-14
MX384083B MX384083B (es) 2025-03-14

Family

ID=52826750

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016005166A MX384083B (es) 2013-10-22 2014-10-21 Derivados de tirosina y composiciones que los comprenden.

Country Status (23)

Country Link
US (2) US9585841B2 (es)
EP (1) EP3060200B1 (es)
JP (1) JP6684210B2 (es)
KR (1) KR102292206B1 (es)
CN (1) CN106232105A (es)
AU (1) AU2014340263B2 (es)
CA (1) CA2927980C (es)
CY (1) CY1124386T1 (es)
DK (1) DK3060200T3 (es)
ES (1) ES2879947T3 (es)
HR (1) HRP20210999T1 (es)
HU (1) HUE055110T2 (es)
IL (1) IL245173B (es)
LT (1) LT3060200T (es)
MX (1) MX384083B (es)
PH (1) PH12016500729A1 (es)
PL (1) PL3060200T3 (es)
PT (1) PT3060200T (es)
RS (1) RS62216B1 (es)
SI (1) SI3060200T1 (es)
SM (1) SMT202100437T1 (es)
WO (1) WO2015061288A1 (es)
ZA (1) ZA201602770B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9585841B2 (en) 2013-10-22 2017-03-07 Tyme, Inc. Tyrosine derivatives and compositions comprising them
US20170333451A1 (en) * 2016-05-18 2017-11-23 Tyme, Inc. Dihydrotestosterone and dihydrotestosterone derivatives and promoters in the treatment of cancer
EP3541411A1 (en) * 2016-11-15 2019-09-25 Tyme, Inc. Pharmaceutical compositions and methods for the treatment of cancer
EP3548086A1 (en) * 2016-11-30 2019-10-09 Tyme, Inc. Tyrosine derivatives and compositions comprising them
JP7300394B2 (ja) 2017-01-17 2023-06-29 ヘパリジェニックス ゲーエムベーハー 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害
JP7171611B2 (ja) * 2017-04-21 2022-11-15 スティーブン・ホフマン 網膜症を治療するための組成物及び方法
ES2991605T3 (es) * 2017-07-19 2024-12-04 Hoffman Tech Llc Composiciones para el tratamiento de los trastornos relacionados con el estrés
KR20190032250A (ko) * 2017-09-19 2019-03-27 주식회사 스킨큐씨 D-타이로신 또는 이를 포함하는 펩타이드를 포함하는 피부 미백용 조성물
RU2719575C1 (ru) * 2019-02-01 2020-04-21 Общество с ограниченной ответственностью "Центр ранней диагностики нейродегенеративных заболеваний (НДЗ)" Фармацевтическая композиция на основе альфа-метил-п-тирозина и способ ранней диагностики болезни Паркинсона
BR112021022784A2 (pt) * 2019-05-14 2022-03-22 Tyme Inc Composições e métodos para tratamento do câncer
WO2021076723A1 (en) * 2019-10-15 2021-04-22 Tyme, Inc. Alkylesters of alpha-methyl-dl-tyrosine for use in treating cancer
IL294803A (en) * 2020-01-17 2022-09-01 Tyme Inc Tyrosine derivatives for modulating cancer
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections
WO2023128791A1 (ru) * 2021-12-30 2023-07-06 Общество С Ограниченной Ответственностью "Центр Ранней Диагностики Нейродегенеративных Заболеваний" Комбинированное лекарственное средство для ранней диагностики болезни паркинсона

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4189604A (en) 1975-07-22 1980-02-19 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Bestatin
CA1108180A (en) 1976-07-21 1981-09-01 Hamao Umezawa Analogs of bestatin
US4165382A (en) 1977-10-17 1979-08-21 Jose Pozuelo Method of pharmacologically treating schizophrenia with alpha-methyl-para-tyrosine
US4117161A (en) 1977-05-16 1978-09-26 Jose Pozuelo Method of pharmacologically treating drug addiction with alpha-methyl-para-tyrosine
US4389415A (en) 1978-01-24 1983-06-21 Merck & Co., Inc. Method of treating hypertension
US5206018A (en) 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US5674839A (en) 1987-05-22 1997-10-07 Competitive Technologies, Inc. Cyclic analogs of alpha-MSH fragments
US5683981A (en) 1987-05-22 1997-11-04 Competitive Technologies, Inc. Cyclic bridged analogs of α-MSH and methods thereof
JP2668880B2 (ja) * 1987-06-23 1997-10-27 日本油脂株式会社 被覆アミノ酸類の製造方法
US4806360A (en) * 1987-10-23 1989-02-21 Advanced Polymer Systems Synthetic melanin aggregates
US5073541A (en) 1987-11-18 1991-12-17 Administrators Of The Tulane Educational Fund Treatment of small cell lung cancer with somatostatin analogs
JPH02286602A (ja) * 1989-04-28 1990-11-26 Nippon Tokushu Noyaku Seizo Kk 徐放性農薬粒剤
US5225435A (en) 1990-05-18 1993-07-06 Yale University Soluble melanin
US5310539A (en) * 1991-04-15 1994-05-10 Board Of Regents, The University Of Texas System Melanin-based agents for image enhancement
WO1994010968A1 (en) * 1992-11-19 1994-05-26 Bristol-Myers Squibb Company Compositions and methods for temporarily coloring hair using solubilized melanin
GB2290379A (en) 1993-03-04 1995-12-20 Mini Agriculture & Fisheries Selective binding materials and assays
EP0696919B1 (en) 1993-04-05 2002-01-30 Competitive Technologies, Inc. Diagnosis and treatment of erectile dysfunction
US8828432B2 (en) * 1996-10-28 2014-09-09 General Mills, Inc. Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles
IT1291633B1 (it) 1997-04-22 1999-01-11 Pharmaconsult S A S Uso dell'alfa-metil-p-tirosina per inibire la produzione di melanina nei melanociti dell'iride
US20030059471A1 (en) 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
IL138214A0 (en) 1998-03-09 2001-10-31 Zealand Pharmaceuticals As Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
WO2000010507A2 (en) 1998-08-21 2000-03-02 The Children's Medical Center Corporation Use of melanin for inhibition of angiogenesis and macular degeneration
US20060052319A9 (en) * 2000-04-03 2006-03-09 Sudhir Agrawal Sensitization of cells to cytotoxic agents using oligonucleotides directed to nucleotide excision repair or transcritpion coupled repair genes
US20030114362A1 (en) 2001-06-08 2003-06-19 Novaspin Biotech Gmbh Penta-or tetrapeptide binding to somatostatin receptors and the use of the same
AU2002359855B2 (en) * 2001-12-21 2008-08-21 David S. Soane Use of oligomers and polymers for drug solublization, stabilization, and delivery
US8620406B2 (en) * 2004-01-23 2013-12-31 Boston Scientific Scimed, Inc. Medical devices visible by magnetic resonance imaging
EP1718145A4 (en) * 2004-02-02 2012-03-07 Biosight Ltd CONJUGATES FOR CANCER THERAPY AND DIAGNOSIS
EP1768692B8 (en) * 2004-07-01 2015-06-17 Yale University Targeted and high density drug loaded polymeric materials
DE602005014442D1 (de) 2005-03-11 2009-06-25 Gpc Biotech Ag Antiproliferative Kombinations-Therapie mit Satraplatin oder JM118 und Docetaxel
WO2006099288A2 (en) 2005-03-11 2006-09-21 Indevus Pharmaceuticals, Inc. Controlled release formulations of octreotide
JP4390845B2 (ja) * 2005-04-01 2009-12-24 インテザイン テクノロジーズ， インコーポレイテッド 薬物送達のためのポリマーミセル
US8758723B2 (en) * 2006-04-19 2014-06-24 The Board Of Regents Of The University Of Texas System Compositions and methods for cellular imaging and therapy
WO2007120153A1 (en) 2006-04-19 2007-10-25 The Board Of Regents Of The University Of Texas System Compositions and methods for cellular imaging and therapy
JP2009536186A (ja) * 2006-05-08 2009-10-08 アステックス・セラピューティクス・リミテッド 癌処置のためのジアゾール誘導体の医薬組合せ
CN101138634A (zh) * 2006-09-07 2008-03-12 于保法 用于治疗肿瘤的组合物
FR2918990B1 (fr) * 2007-07-20 2012-12-21 Innov Ia Procede de preparation de compositions pulverulentes stables
WO2009054001A1 (en) 2007-10-22 2009-04-30 Biocon Limited A pharmaceutical composition and a process thereof
CN101965192A (zh) 2008-03-07 2011-02-02 法马马有限公司 改善的抗肿瘤治疗
EP2106806A1 (en) * 2008-03-31 2009-10-07 Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. Nanoparticles for targeted delivery of active agents to the lung
WO2009131631A1 (en) 2008-04-14 2009-10-29 Poniard Pharmaceuticals, Inc. Rapamycin analogs as anti-cancer agents
KR101078302B1 (ko) * 2008-05-29 2011-10-31 (주)프로넥스 약물전달체
CA2734828C (en) 2008-08-20 2018-07-24 J. Silvio Gutkind Chemoprevention of head and neck squamous cell carcinomas
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
EP2416792A4 (en) 2009-04-10 2012-10-24 Haiyan Qi NOVEL ANTI-AGING AGENTS AND METHODS OF IDENTIFICATION
WO2011112576A1 (en) 2010-03-10 2011-09-15 Ambrilia Biopharma Inc. Microspheres for sustained release of octreotide acetate
CN103153303A (zh) * 2010-07-18 2013-06-12 尼基制药公司 使用钌络合物的联合疗法
EP3488848A1 (en) 2012-01-17 2019-05-29 Tyme, Inc. Tyrosine hydroxylase inhibitors for use in treating cancer
US9724657B2 (en) * 2013-10-22 2017-08-08 Tyme, Inc. High-speed centrifugal mixing devices and methods of use
US9585841B2 (en) * 2013-10-22 2017-03-07 Tyme, Inc. Tyrosine derivatives and compositions comprising them

Also Published As

Publication number Publication date
IL245173A0 (en) 2016-06-30
CA2927980C (en) 2022-07-19
CA2927980A1 (en) 2015-04-30
HUE055110T2 (hu) 2021-10-28
AU2014340263B2 (en) 2019-11-21
LT3060200T (lt) 2021-08-25
US20150112116A1 (en) 2015-04-23
DK3060200T3 (da) 2021-07-12
HRP20210999T1 (hr) 2021-11-26
EP3060200A1 (en) 2016-08-31
US11058638B2 (en) 2021-07-13
ZA201602770B (en) 2017-04-26
US9585841B2 (en) 2017-03-07
IL245173B (en) 2020-10-29
CN106232105A (zh) 2016-12-14
US20170172924A1 (en) 2017-06-22
EP3060200B1 (en) 2021-05-26
PT3060200T (pt) 2021-07-07
KR102292206B1 (ko) 2021-08-24
SI3060200T1 (sl) 2021-11-30
MX384083B (es) 2025-03-14
PH12016500729A1 (en) 2016-05-30
WO2015061288A1 (en) 2015-04-30
AU2014340263A1 (en) 2016-05-19
RS62216B1 (sr) 2021-09-30
KR20160072239A (ko) 2016-06-22
JP2016534071A (ja) 2016-11-04
NZ719457A (en) 2021-02-26
JP6684210B2 (ja) 2020-04-22
ES2879947T3 (es) 2021-11-23
PL3060200T3 (pl) 2021-10-11
SMT202100437T1 (it) 2021-09-14
CY1124386T1 (el) 2022-07-22

Similar Documents

Publication Publication Date Title
MX2016005166A (es) Derivados de tirosina y composiciones que los comprenden.
SV2018005709A (es) 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa
AR102712A1 (es) Agonistas parciales del receptor de insulina
CR20150634A (es) Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina
UY35500A (es) Indazoles sustituidos con heteroarilo
CO2017012995A2 (es) Derivados análogos de heteroarilos/arilo actvos como reguladores nrf2 y composiciones farmacéuticas de los mismos
CR20140450A (es) Composicion para el control de plagas que incluye un derivado de iminopiridina novedoso
DOP2016000145A (es) Reguladores de nrf2
CL2016002772A1 (es) Composiciones de insulina de rápida acción
MX2017006283A (es) Peptidos macrociclicos utiles como inmunomoduladores.
CR20160154A (es) Ácidos grasos octanoico, nonanoico y decanoico con un adulticida piretroide
BR112017012210A2 (pt) solução conservante de célula, uso da mesma e método de produção de solução conservante de célula
CL2016001210A1 (es) Análogos de bicalutamida o (s)- bicalutamida como compuestos activadores de la exocitosis para su uso en el tratamiento de un desorden de acúmulo lisosomal o glucogenosis.
CR20160002A (es) Formulación estable líquida de etelcalcetide (amg 461)
DOP2016000073A (es) Composiciones y métodos para inhibir la expresión del gen alas1
CO2018005753A2 (es) Composición hemostática
MX2017001352A (es) Derivados de pirrolidinona como inhibidores de metionina aminopeptidasa 2 (metap-2).
MX2017003476A (es) Compuestos citotoxicos y anti-mitoticos, y metodos para usar los mismos.
DK3404759T3 (da) Forbedret katodeformulering til overlevelseslokaliseringslys
CL2016000038A1 (es) Piraxolo-piridinaminas sustituidas
UY36292A (es) Compuestos de tetrahidroquinolina para su uso como inhibidores de bromodominios
MX373197B (es) Formulaciones estables de undecanoato de testosterona.
BR112016012552A8 (pt) derivado de cromona como um antagonista do receptor d3 de dopamina, seu uso e sua composição farmacêutica
PE20160121A1 (es) Formulaciones de factor viii recombinantes
CR20150037A (es) Aparatos y técnicas para la colocación subterránea de uno o más elementos